Abstract:Endothelial dysfunction is an early consequence of vascular inflammation and a driver of coronary atherosclerotic disease leading to myocardial infarction. The red blood cells (RBCs) mediate endothelial dysfunction in patients at cardiovascular risk, but their role in patients with acute myocardial infarction is unknown. This study aimed to investigate if RBCs from patients with ST-elevation myocardial infarction (STEMI) induced endothelial dysfunction and the role of systemic inflammation in this effect. RBCs from patients with STEMI and aged-matched healthy controls were coincubated with rat aortic segments for 18 h followed by evaluation of endothelium-dependent (EDR) and endothelium-independent relaxation (EIDR). RBCs and aortic segments were also analyzed for arginase and oxidative stress. The patients were divided into groups depending on C-reactive protein (CRP) levels at admission. RBCs from patients with STEMI and CRP levels ≥2 mg/L induced impairment of EDR, but not EIDR, compared with RBCs from STEMI and CRP <2 mg/L and healthy controls. Aortic expression of arginase 1 was increased following incubation with RBCs from patients with STEMI and CRP ≥2, and arginase inhibition prevented the RBC-induced endothelial dysfunction. RBCs from patients with STEMI and CRP ≥2 had increased reactive oxygen species compared with RBCs from patients with CRP <2 and healthy controls. Vascular inhibition of NADPH oxidases and increased dismutation of superoxide improved EDR. RBCs from patients with STEMI and low-grade inflammation induce endothelial dysfunction through a mechanism involving arginase 1 as well as increased RBC and vascular superoxide by NADPH oxidases.NEW & NOTEWORTHY Red blood cells from patients with STEMI and systemic inflammation induce endothelial dysfunction ex vivo. The RBC-induced endothelial dysfunction is mediated through increased arginase 1 and a shift in the redox balance toward oxidative stress. Inhibition of arginase or free radicals attenuates the impairment of endothelial function. The study suggests that red blood cells deserve attention as a key player in systemic inflammation and STEMI.

Red blood cells: a new target to prevent cardiovascular disease?

Erythrocyte-Derived microRNAs: Emerging Players in Cardiovascular and Metabolic Disease

Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia

Red blood cell eNOS: a major player in regulating cardiovascular health.

Discovery of new therapeutic redox targets for cardioprotection against ischemia/reperfusion injury and heart failure

Redox Roles of Reactive Oxygen Species in Cardiovascular Diseases

Red blood cells: the forgotten player in hemostasis and thrombosis

Targeting Nrf2 signaling pathway: new therapeutic strategy for cardiovascular diseases

RNA Binding Proteins: Mechanistic Considerations and Perspectives in Controlling Cardiovascular Diseases

Role of red blood cells in clinically relevant bleeding tendencies and complications

Effects of REDOX in Regulating and Treatment of Metabolic and Inflammatory Cardiovascular Diseases

Reactive Oxygen Species in Cardiovascular Diseases: an Update

Red Blood Cell Homeostasis: Pharmacological Interventions to Explore Biochemical, Morphological and Mechanical Properties

Red blood cells from patients with ST-elevation myocardial infarction and elevated C-reactive protein levels induce endothelial dysfunction

Recent advances with erythrocytes as therapeutics carriers

Red Blood Cells as Potential Repositories of MicroRNAs in the Circulatory System

The red blood cell as a mediator of endothelial dysfunction in patients with familial hypercholesterolemia and dyslipidemia

Anthocyanins in Vascular Health and Disease: Mechanisms of Action and Therapeutic Potential

The pathophysiology and consequences of red blood cell storage

Red Blood Cell Transfusion Strategies in Cardiovascular Interventions